Jibe Ventures

Jibe Ventures, based in Tel Aviv, is an early-stage Israeli venture firm founded by operators with a thesis built around backing technical founders constructing AI-native applications and digital health infrastructure. The fund’s identity is shaped by an operator-led perspective: investment decisions are made by people who have built products themselves, and portfolio support reflects that orientation.

For AI healthcare founders, the relevant thesis covers AI-native applications and digital health infrastructure where the underlying technology is genuinely AI-driven, where the team has the technical chops to build durable products, and where the wedge into healthcare is well-defined. Companies that apply machine learning to clinical workflows, decision support, imaging, documentation, or operational data tend to fit. Pure consumer wellness, devices, and biotech are not core. Companies labeled as AI but whose actual product is conventional software with light ML will not clear conviction.

Check sizes range from $1M to $5M at entry, deployed at seed and Series A. Jibe leads and co-leads in priced rounds and reserves capital for follow-on. Geography is principally Israel, with portfolio companies typically operating globally and pursuing the US as the primary commercial market. Syndicate partners include other Israeli early-stage specialists, US AI and enterprise software funds, and selected angels in the AI ecosystem. Reserve strategy and follow-on participation are aligned with the typical timelines of AI-native companies, which can scale faster than conventional enterprise software when the product works.

The team is led by partners with operating backgrounds in technology, with active engagement at the board level. Help focuses on technical hiring, product strategy, AI-specific engineering questions, customer development, and downstream financing. The operator orientation makes the fund particularly useful to first-time founders or technical founders who need help translating product into commercial motion.

Founders should approach Jibe with a clear technical thesis, a credible articulation of why AI is the substantive engine of the product, and an honest view of the data strategy. Introductions through portfolio CEOs, US and Israeli AI-specialist VCs, or operators in the AI community are the highest-signal path in. The right time to engage is when the team is assembled, an early product is in motion, and the next round is being structured. Founders pitching general digital health, devices, or biotech will not find fit. Companies whose AI claims are decorative will struggle to clear diligence. For founders building genuinely AI-native healthcare applications who want operator support alongside capital, Jibe offers a thesis-aligned and operationally useful early-stage partner.